LATEST NEWS

2022/07/04

    Novation and UofMontreal present at Target ALS annual meeting in Boston, MA

2022/01/19

    Dr. Roland Bürli joins Novation's Scientific Advisory Board

2021/04/30

    Novation and UofMontreal/CRCHUM consortia present at Target ALS annual meeting

2020/07/13

    Target ALS award for Novation and UofMontreal/CRCHUM collaboration

2018/12/04

    Novation presents at first RNA-targeted drug discovery summit

2016/01/19

    Dr. Andrew MacKenzie joins Novation's Scientific Advisory Board

2016/01/01

    Novation files US patent on oral cytokine inhibitor

2013/05/07

    Novation establishes Research Collaboration with Boehringer Ingelheim

2013/04/22

    Novation receives Notice of Issuance by Canadian Patent Office for QUEST mRNA Drug Discovery Technology

2012/10/22

    Novation receives Notice of Allowance by Canadian Patent Office for QUEST mRNA Drug Discovery Technology

2010/07/20

    Novation receives contribution from NRC IRAP

2009/06/11

    Novation and Cancer Therapeutics collaborate on new cancer therapies

2009/06/02

    Notice of Allowance from US Patent Office for Quest Drug Discovery technology

2009/01/07

    Quest drug discovery assay available for identifying inhibitors of IL-6

2008/11/17

    Quest oncology drug discovery assays for intractable cancer targets

2008/10/30

    Drug discovery assay for identifying new therapeutics for neurological diseases

2008/09/11

    Dr. Inder Verma joins Novation's Scientific Advisory Board

2007/09/04

    Novation receives Notice of Intent to Grant from European Patent Office

2006/02/05

    Dr. Alan Lewis and Dr. Tim Harris appointed to Novation's Board of Directors

2005/11/23

    Novation Commences mRNA Small Molecule Drug Discovery Project with Novartis